Want to see TSE:TELO full AI Analyst Report?
TELO Stock Chart & Stats
C$0.04
C$0.01(8.00%)
At close: 4:00 PM EST
C$0.04
C$0.01(8.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.11
Previous CloseN/A
Volume60.50K
Average Volume (3M)29.30K
Market Cap
C$4.32M
Enterprise ValueC$5.86M
Total Cash (Recent Filing)C$975.48K
Total Debt (Recent Filing)C$1.32M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding100,430,470
10 Day Avg. Volume22,350
30 Day Avg. Volume29,304
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)18.74
Price to Sales (P/S)0.00
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic PlatformOwning a proprietary measurement platform creates durable product differentiation and a route to recurring revenue once commercialized. TeloView can underpin multiple diagnostics, licensing, and service models across research and clinical settings, supporting longer-term monetization and adoption dynamics.
Large Addressable MarketsTargeting oncology and age-related disease workflows aligns the company with structurally growing diagnostic demand. These markets favor validated biomarkers and monitoring tools, offering persistent clinical need and potential repeat usage by providers, which supports durable revenue opportunities if clinical utility is proven.
Lean Operating StructureA very small headcount implies a low fixed-cost base, which can extend runway and focus R&D spend on core product development. For a pre-commercial biotech, lean operations reduce cash required to reach key milestones and can make limited financing stretch further during commercialization efforts.
Bears Say
No Revenue / Pre-commercialZero revenue means the business model remains unproven and the company lacks operating cash inflows to fund growth. Long-term viability depends on successful commercialization or recurring service adoption; absent revenue, the firm must rely on external financing, increasing execution and dilution risk over months.
Negative Equity And Rising LeverageNegative equity combined with new debt materially reduces financial flexibility and increases solvency risk. This structural imbalance can constrain future financing options, raise cost of capital, and limit ability to invest in commercial rollout or clinical validation without dilutive or costly funding.
Consistent Negative Cash FlowSustained operating and free cash outflows indicate ongoing cash burn that will require new financing to sustain operations and fund commercialization. Persistent negative cash flow increases the probability of dilution, delays in product development, and constrained investment in market access or regulatory activities over the medium term.
Telo Genomics Corp News
TELO FAQ
What was Telo Genomics Corp’s price range in the past 12 months?
Telo Genomics Corp lowest stock price was C$0.04 and its highest was C$0.11 in the past 12 months.
What is Telo Genomics Corp’s market cap?
Telo Genomics Corp’s market cap is C$4.32M.
When is Telo Genomics Corp’s upcoming earnings report date?
Telo Genomics Corp’s upcoming earnings report date is Nov 02, 2026 which is in 116 days.
How were Telo Genomics Corp’s earnings last quarter?
Telo Genomics Corp released its earnings results on Jun 02, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.006.
Is Telo Genomics Corp overvalued?
According to Wall Street analysts Telo Genomics Corp’s price is currently Overvalued.
Does Telo Genomics Corp pay dividends?
Telo Genomics Corp does not currently pay dividends.
What is Telo Genomics Corp’s EPS estimate?
Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telo Genomics Corp have?
Telo Genomics Corp has 100,430,470 shares outstanding.
What happened to Telo Genomics Corp’s price movement after its last earnings report?
Telo Genomics Corp reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Telo Genomics Corp?
Currently, no hedge funds are holding shares in TSE:TELO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Telo Genomics Corp
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.
Technical Analysis
BioMark Diagnostics
―
StageZero Life Sciences Ltd
―
Kane Biotech
―
Sona Nanotech Inc
―
Avricore Health
―